Mingzhong Li

机构：Tiande (China), Tiandi Science & Technology (China), De Montfort University · ORCID：0000-0002-9532-9049

发表论文 212 篇 · 总被引 3133 次 · h-index 27

代表论文

• Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma (2023 · Annals of Oncology · 被引 49)
• Preparation and Characterization of Ternary Complexes to Improve the Solubility and Dissolution Performance of a Proteolysis-Targeting Chimera Drug (2025 · Pharmaceutics · 被引 9)
• Amorphous solid dispersion formulation of pimobendan for bioavailability enhancement: A comprehensive study on miscibility, interactions, and in vitro dissolution behavior (2025 · Journal of Drug Delivery Science and Technology · 被引 7)
• LBA24 Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: Results from a randomized phase III study (2025 · Annals of Oncology · 被引 5)
• Iterative assembly of $^{171}$Yb atom arrays with cavity-enhanced optical lattices (2024 · arXiv (Cornell University) · 被引 5)
• Multi-Objective Optimization of a Novel Ribbed Honeycomb Heat Sink for an Electro-Hydrostatic Actuator (2023 · Processes · 被引 5)